BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 2187120)

  • 1. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teniposide in lymphomas and leukemias.
    Sonneveld P
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):59-64. PubMed ID: 1411640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epipodophyllotoxins in the treatment of childhood cancer.
    Rivera GK; Pui CH; Santana VM; Pratt CB; Crist WM
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S89-95. PubMed ID: 8070034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.
    Grem JL; Hoth DF; Leyland-Jones B; King SA; Ungerleider RS; Wittes RE
    J Clin Oncol; 1988 Feb; 6(2):351-79. PubMed ID: 3276827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in relation to drug action.
    Muggia FM; McVie G
    NCI Monogr; 1987; (4):129-33. PubMed ID: 2819724
    [No Abstract]   [Full Text] [Related]  

  • 6. Etoposide in the treatment of leukemias.
    Bishop JF
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):33-8. PubMed ID: 1492226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide.
    Verdeguer A; Ruiz JG; Ferris J; Esquembre C; Tasso MJ; Fernandez JM; Prieto F; Castel V
    Med Pediatr Oncol; 1992; 20(1):48-52. PubMed ID: 1727211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia.
    Rivera GK
    J Clin Oncol; 1988 Feb; 6(2):191-3. PubMed ID: 3276820
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
    Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT
    N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
    Navajas Gutiérrez A; Bezanilla Regato JL; Moya Calderón E; Piñán MA
    An Esp Pediatr; 1988 Oct; 29 Suppl 34():91-3. PubMed ID: 3214046
    [No Abstract]   [Full Text] [Related]  

  • 13. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
    Estlin EJ; Lowis SP; Hall AG
    Br J Haematol; 2000 Jul; 110(1):29-40. PubMed ID: 10930977
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia.
    Rivera GK; Evans WE
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):51-8. PubMed ID: 1411639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
    Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
    Gutierrez ML; Crooke ST
    Cancer Treat Rev; 1979 Sep; 6(3):153-64. PubMed ID: 394834
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
    Rodman JH; Sunderland M; Kavanagh RL; Ochs J; Yalowich J; Evans WE; Rivera GK
    Cancer Res; 1990 Jul; 50(14):4267-71. PubMed ID: 2194652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
    Sinkule JA
    Pharmacotherapy; 1984; 4(2):61-73. PubMed ID: 6326063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
    Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
    Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.